Page last updated: 2024-11-11

1-stearoyl-2-oleoyl-sn-glycerol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-octadecanoyl-2-[(9Z)-octadecenoyl]-sn-glycerol : A 1,2-diacyl-sn-glycerol that has stearoyl and oleoyl as the 1- and 2-acyl groups respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6443547
CHEBI ID75468
SCHEMBL ID7917740
MeSH IDM0223812

Synonyms (25)

Synonym
1-octadecanoyl-2-(9z-octadecenoyl)-sn-glycerol
LMGL02010043 ,
dg(18:0/18:1(9z)/0:0)[iso2]
dg(18:0_18:1)
dg(18:0/18:1/0:0)[iso2]
[(2s)-3-hydroxy-2-[(z)-octadec-9-enoyl]oxypropyl] octadecanoate
1-stearoyl-2-oleoyl-sn-glycerol
sn-sodg
9-octadecenoic acid (z)-, 1-(hydroxymethyl)-2-((1-oxooctadecyl)oxy)ethyl ester, (s)-
53702-48-0
1-octadecanoyl-2-[(9z)-octadecenoyl]-sn-glycerol
(2s)-1-hydroxy-3-(octadecanoyloxy)propan-2-yl (9z)-octadec-9-enoate
CHEBI:75468
SCHEMBL7917740
dg(18:0/18:1(9z)/0:0)
dag(18:0/18:1n9)
diacylglycerol(18:0/18:1n9)
dg(18:0/18:1n9)
dg(18:0/18:1w9)
diacylglycerol(18:0/18:1w9)
dag(18:0/18:1w9)
1-steraoyl-2-oleoyl-sn-glycerol
Q27105044
DTXSID301150231
(1s)-1-(hydroxymethyl)-2-[(1-oxooctadecyl)oxy]ethyl (9z)-9-octadecenoate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
1,2-diacyl-sn-glycerol
1-stearoyl-2-oleoylglycerolA 1,2-diglyceride with stearoyl and oleoyl as the acyl groups.
diacylglycerol 36:1A diglyceride in which the two acyl groups contain a total of 36 carbons and 1 double bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (43)

PathwayProteinsCompounds
phospholipid biosynthesis (PE(18:0/18:1(9Z)))717
Triacylglycerol Degradation TG(18:0/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/20:0)513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/22:0)513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/22:1(13Z))513
Phosphatidylcholine Biosynthesis PC(18:0/18:1(9Z))620
Phosphatidylethanolamine Biosynthesis PE(18:0/18:1(9Z))516
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:0)514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:1(9Z))513
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:1(11Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:2(9Z,12Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:0)513
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/22:0)514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/24:0)514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/14:1(9Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/16:1(9Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:1(11Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:3(5Z,8Z,11Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/22:1(13Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/24:1(15Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:3(6Z,9Z,12Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/22:2(13Z,16Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:3(9Z,12Z,15Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:2(11Z,14Z))513
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:3(8Z,11Z,14Z))513
Lipids measured in liver metastasis from breast cancer629
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/18:1(9Z)) | PE(18:0/18:1(9Z))617

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (50.00)18.2507
2000's2 (33.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.36 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]